objobjobj, page-22

Ha, I always guessed you have some lucky fortune telling hotline to the future, adbm. This seems to confirm it!

Your heavy exposure to OBJ will function as a lotto ticket with much less risk involved, so my humble assessment..)


amg,
thank you, hope you had an enjoyable time too!
The capping is so blunt now that the active party/ies do not even attempt to hide it anymore.
This usually marks the end of the process to supress share price prior to news, in my opinion.



GSK indeed might prove itself to be the biggest and best positioned muscle behind our deal forming engine. The GSK announcement was the potential company maker, especially when one considers that GSK not only develops a FIM program but also could have a drug in testing for its pharmaceutical division.
GSK could well be purchasing licences for exclusive use of several of our products.

This would explain why OBJ concentrates on a European partnering since some time now.
We will, in all likelihood know soon.